Apeiron Investment Group

Operates a sports organization dedicated to redefining athletic competition by integrating science and human performance. Offers state-of-the-art medical profiling, athlete compensation, and a platform for enhanced competition, prioritizing athlete safety.

Rejuveron Life Sciences AG is a biotechnology company based in Zug, Switzerland, founded in 2019. The company focuses on developing and investing in innovative drugs and technologies aimed at promoting healthy aging and extending lifespan. As a fully integrated platform, Rejuveron combines its investment strategies with a commitment to advancing therapies that address age-related conditions, leveraging both scientific research and entrepreneurial initiatives in the life sciences sector.

NextMarkets GmbH, founded in 2014 and based in Cologne, Germany, offers a user-friendly web and mobile application tailored for private investors engaging in capital markets. The platform allows users to trade a wide range of financial instruments, including contracts for difference (CFDs) on equities, foreign exchange, bonds, and commodities. Recognizing that a significant majority of private investors struggle in the stock market due to behavioral economic factors, NextMarkets aims to empower its users by providing educational resources, training, and strategies that enhance their trading experience. The company's mission is to promote a more informed and sustainable approach to investing, enabling users to better understand market dynamics and make informed trading decisions.

Rejuveron Life Sciences AG is a biotechnology company based in Zug, Switzerland, founded in 2019. The company focuses on developing and investing in innovative drugs and technologies aimed at promoting healthy aging and extending lifespan. As a fully integrated platform, Rejuveron combines its investment strategies with a commitment to advancing therapies that address age-related conditions, leveraging both scientific research and entrepreneurial initiatives in the life sciences sector.

Mynaric AG, established in 2009 and headquartered in Gilching, Germany, specializes in laser communication solutions for high-speed, long-distance wireless data transmission between moving objects. The company offers a range of terminals including air-to-ground, air-to-air, space terminals, and optical ground stations, catering to applications in space, air, and ground sectors. Its products facilitate secure, high-data rate connectivity for satellite constellations, airborne networks, and other mobility-based applications.

Cambrian BioPharma specializes in developing innovative therapeutics aimed at extending healthspan, the period of life spent in good health. As a Distributed Development Company (DisCo), it focuses on advancing scientific breakthroughs targeting biological drivers of aging, initially treating specific diseases and later deploying these interventions preventatively to enhance overall quality of life.

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company based in Menlo Park, California, that specializes in developing therapeutic agents for hematopoietic stem cell transplants and gene therapies. Founded in 2018, the company aims to enhance the safety and efficacy of conditioning agents to broaden the application of curative therapies. Jasper's lead product, JSP191, is a humanized monoclonal antibody currently in clinical development, designed to act as a conditioning agent by selectively clearing hematopoietic stem cells from bone marrow in patients undergoing stem cell transplants. The company also utilizes an engineered hematopoietic stem cells platform to address the limitations of transplant grafts, thereby increasing the accessibility of both allogeneic and autologous gene-edited hematopoietic stem cell therapies for a larger patient population.

Upmin is a real estate technology company that operates an online platform for property management. It automates various processes such as accounting, utility bill payments, tenant management, and property maintenance, saving landlords and owners time and money. Additionally, Upmin offers optional rental services including tenant search assistance from advertising to handover.

Olsam Group is a commerce company that acquires and operates top Amazon third-party and other direct-to-consumer eCommerce brands. It employs a technology-driven approach, focusing on scaling acquired brands to achieve hypergrowth on global digital marketplaces.

Isar Aerospace is a space technology company focused on developing automated production methods for rockets. The company designs launch vehicles that facilitate the deployment and resupply of satellite constellations, aiming to provide low-cost and flexible access to space for small satellites. With an emphasis on sustainability, Isar Aerospace offers environmentally friendly solutions for propelling small launchers and upper-stage vehicles, thereby lowering entry barriers for clients seeking affordable and reliable space access.

Founded in 2019, Ksana Health specializes in digital mental health solutions. Its platform collects user data related to mental health and facilitates its transfer to healthcare practitioners for improved patient care.

Alto Neuroscience is a clinical-stage biopharmaceutical company focused on redefining psychiatry through the integration of patient neurobiology into the drug development process. Utilizing an AI-enabled biomarker platform, the company combines diverse information about patients' brain activity and behavior to create personalized and effective treatment options. Alto Neuroscience is developing several clinical assets, including ALTO-100, ALTO-202, ALTO-101, and ALTO-300, primarily targeting depressive disorders and schizophrenia, identified through independent brain-based biomarkers. By moving away from traditional trial-and-error methods, the company aims to align its innovative therapies with the specific needs of patients, ultimately improving the management of mental health conditions.

ChemomAb Ltd. is a clinical-stage biotechnology company based in Tel Aviv, Israel, specializing in the development of therapeutic antibodies for autoimmune and inflammatory diseases. The company focuses on addressing fibrosis-related conditions that present significant unmet medical needs. ChemomAb's lead product, CM-101, is a monoclonal antibody designed to inhibit the activity of the soluble protein CCL24, which plays a crucial role in promoting fibrosis and inflammation. CM-101 is currently undergoing clinical development, with a primary emphasis on orphan diseases such as Primary Sclerosing Cholangitis (PSC) and Systemic Sclerosis (SSc). The company is advancing three Phase 2 clinical trials for CM-101 in various fibrotic indications, with data anticipated to be reported in the near future.

Cambrian BioPharma specializes in developing innovative therapeutics aimed at extending healthspan, the period of life spent in good health. As a Distributed Development Company (DisCo), it focuses on advancing scientific breakthroughs targeting biological drivers of aging, initially treating specific diseases and later deploying these interventions preventatively to enhance overall quality of life.

Sensei Biotherapeutics is a clinical-stage biotechnology company developing next-generation cancer immunotherapies. It focuses on novel biologics that modulate the immune system to treat cancers with unmet need, using its ImmunoPhage discovery platform to study the tumor microenvironment and identify differentiated mechanisms that engage both innate and adaptive immunity. The company pursues a Tumor Microenvironment Activated Biologics TMAb platform to selectively disable immunosuppressive signals or activate immunostimulatory signals within the tumor microenvironment. Headquartered in Gaithersburg, Maryland with an office in Boston, Massachusetts, Sensei Biotherapeutics has four investigational product candidates in development: SNS-101, SNS-102, SNS-103, and SNS-201.

MagForce AG is a medical device company based in Berlin, Germany, specializing in nanotechnology-based cancer treatment. The company has developed NanoTherm therapy, which targets solid tumors by generating localized heat through the activation of superparamagnetic nanoparticles. Its product offerings include NanoTherm, a ferrofluid containing superparamagnetic iron oxide nanoparticles that respond to alternating magnetic fields, and NanoActivator, a device that applies the magnetic field for therapeutic purposes. Additionally, MagForce provides NanoPlan, a software tool that assists in treatment planning using bioheat transfer equations. Founded in 1997, MagForce focuses on innovative solutions to enhance cancer treatment efficacy.

Isar Aerospace is a space technology company focused on developing automated production methods for rockets. The company designs launch vehicles that facilitate the deployment and resupply of satellite constellations, aiming to provide low-cost and flexible access to space for small satellites. With an emphasis on sustainability, Isar Aerospace offers environmentally friendly solutions for propelling small launchers and upper-stage vehicles, thereby lowering entry barriers for clients seeking affordable and reliable space access.

ATAI Life Sciences is a biotechnology company focused on developing therapies for mental health disorders, leveraging psychedelic compounds and neuroscience-based approaches. It operates a platform for mental health drug discovery and development and collaborates with partners and research institutions to advance its pipeline, which includes VLS-01, a buccal-film DMT candidate for treatment-resistant depression, and EMP-01, an oral MDMA therapy for social anxiety disorder, along with a drug discovery program aimed at identifying non-hallucinogenic 5-HT2A receptor agonists for depression. The company is based in Munich, Germany, with additional offices in Berlin and London.

Sensei Biotherapeutics is a clinical-stage biotechnology company developing next-generation cancer immunotherapies. It focuses on novel biologics that modulate the immune system to treat cancers with unmet need, using its ImmunoPhage discovery platform to study the tumor microenvironment and identify differentiated mechanisms that engage both innate and adaptive immunity. The company pursues a Tumor Microenvironment Activated Biologics TMAb platform to selectively disable immunosuppressive signals or activate immunostimulatory signals within the tumor microenvironment. Headquartered in Gaithersburg, Maryland with an office in Boston, Massachusetts, Sensei Biotherapeutics has four investigational product candidates in development: SNS-101, SNS-102, SNS-103, and SNS-201.

Hotelbird is a technology company that specializes in digitizing the hotel experience through its mobile application. The platform facilitates various aspects of hotel management, including booking, digital check-in and check-out, and payment processing, all aimed at creating a seamless experience for guests. By providing features such as direct booking and digital room keys, Hotelbird enables hotel managers to enhance guest satisfaction and optimize revenue while reducing operational costs. The company's mission is to equip every host with the necessary tools to operate efficiently and deliver an exceptional experience to their guests.

Zenhomes provides a one-stop shop for private landlords and property managers. The company's digital platform simplifies property and tenant management.

Founded in 2012, Springlane operates an online platform specializing in kitchen and cooking products. Initially a shopping club for enthusiasts, it evolved into Germany's leading online retailer in this vertical, offering over 15,000 products from 750 premium brands. Since 2018, Springlane has focused on developing integrated consumer brands, ranking among Europe's most influential food content websites.

ATAI Life Sciences is a biotechnology company focused on developing therapies for mental health disorders, leveraging psychedelic compounds and neuroscience-based approaches. It operates a platform for mental health drug discovery and development and collaborates with partners and research institutions to advance its pipeline, which includes VLS-01, a buccal-film DMT candidate for treatment-resistant depression, and EMP-01, an oral MDMA therapy for social anxiety disorder, along with a drug discovery program aimed at identifying non-hallucinogenic 5-HT2A receptor agonists for depression. The company is based in Munich, Germany, with additional offices in Berlin and London.

Juvenescence is a British Virgin Islands-based company focused on investing in human aging and longevity. It aims to extend both lifespan and healthspan by developing therapeutics that slow aging and treat age-related diseases. The company creates and partners with new ventures, in-licenses compounds, or forms joint ventures to build an ecosystem of assets targeting aging, regeneration, and related diseases.

Super Copper Corp is a mineral exploration company focused on copper. It engages in the acquisition, exploration, and evaluation of resource properties and is developing a copper project in the Atacama region of Chile, an area with robust infrastructure and the presence of major mining companies.